Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma

Sachin S. Saboo, Katherine M. Krajewski, Jyothi P. Jagannathan, Kevin N. O'Regan, Robert Odze, Nikhil Ramaiya, Brian M. Wolpin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) is a rare entity comprising 1-14.2% of all primary liver carcinomas. In this report, we present a case of rapid progression of cHCC-CC, a rare tumor in a 77-year-old Caucasian male patient with hepatitis B-induced cirrhosis, moderately elevated alpha fetoprotein, and imaging and pathologic features of a mixed liver tumor. There was no evidence of metastatic disease in the chest, abdomen or pelvis by computed tomography (CT) scan at the time of diagnosis. Needle biopsy of the segment 8 lesion revealed two discrete histologic components to the tumor: well-differentiated HCC and poorly differentiated adenocarcinoma, consistent with intrahepatic CC. The patient rapidly developed metastatic disease after initial local therapy with hepatic arterial chemoembolization and percutaneous cryoablation, dying within 5 months of diagnosis. Radiofrequency ablation, cryoablation and radioembolization with yttrium-90 microspheres remain possible treatment strategies for patients with cHCC-CC unable to undergo surgical resection. The diagnosis and treatment of cHCC-CC can be challenging due to clinical, imaging and histological features that overlap with pure HCC and CC.

Original languageEnglish (US)
Pages (from-to)37-41
Number of pages5
JournalCancer Imaging
Volume11
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Cholangiocarcinoma
Hepatocellular Carcinoma
Cryosurgery
Liver
Yttrium
Neoplasms
alpha-Fetoproteins
Needle Biopsy
Hepatitis B
Pelvis
Microspheres
Abdomen
Adenocarcinoma
Fibrosis
Thorax
Therapeutics
Tomography
Carcinoma

Keywords

  • Combined hepatocellular carcinoma and cholangiocarcinoma
  • MRI

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Saboo, S. S., Krajewski, K. M., Jagannathan, J. P., O'Regan, K. N., Odze, R., Ramaiya, N., & Wolpin, B. M. (2011). Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma. Cancer Imaging, 11(1), 37-41. https://doi.org/10.1102/1470-7330.2011.0009

Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma. / Saboo, Sachin S.; Krajewski, Katherine M.; Jagannathan, Jyothi P.; O'Regan, Kevin N.; Odze, Robert; Ramaiya, Nikhil; Wolpin, Brian M.

In: Cancer Imaging, Vol. 11, No. 1, 2011, p. 37-41.

Research output: Contribution to journalArticle

Saboo, SS, Krajewski, KM, Jagannathan, JP, O'Regan, KN, Odze, R, Ramaiya, N & Wolpin, BM 2011, 'Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma', Cancer Imaging, vol. 11, no. 1, pp. 37-41. https://doi.org/10.1102/1470-7330.2011.0009
Saboo, Sachin S. ; Krajewski, Katherine M. ; Jagannathan, Jyothi P. ; O'Regan, Kevin N. ; Odze, Robert ; Ramaiya, Nikhil ; Wolpin, Brian M. / Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma. In: Cancer Imaging. 2011 ; Vol. 11, No. 1. pp. 37-41.
@article{b01ae86b9ca44a05b7cd37e81bcabb3d,
title = "Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma",
abstract = "Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) is a rare entity comprising 1-14.2{\%} of all primary liver carcinomas. In this report, we present a case of rapid progression of cHCC-CC, a rare tumor in a 77-year-old Caucasian male patient with hepatitis B-induced cirrhosis, moderately elevated alpha fetoprotein, and imaging and pathologic features of a mixed liver tumor. There was no evidence of metastatic disease in the chest, abdomen or pelvis by computed tomography (CT) scan at the time of diagnosis. Needle biopsy of the segment 8 lesion revealed two discrete histologic components to the tumor: well-differentiated HCC and poorly differentiated adenocarcinoma, consistent with intrahepatic CC. The patient rapidly developed metastatic disease after initial local therapy with hepatic arterial chemoembolization and percutaneous cryoablation, dying within 5 months of diagnosis. Radiofrequency ablation, cryoablation and radioembolization with yttrium-90 microspheres remain possible treatment strategies for patients with cHCC-CC unable to undergo surgical resection. The diagnosis and treatment of cHCC-CC can be challenging due to clinical, imaging and histological features that overlap with pure HCC and CC.",
keywords = "Combined hepatocellular carcinoma and cholangiocarcinoma, MRI",
author = "Saboo, {Sachin S.} and Krajewski, {Katherine M.} and Jagannathan, {Jyothi P.} and O'Regan, {Kevin N.} and Robert Odze and Nikhil Ramaiya and Wolpin, {Brian M.}",
year = "2011",
doi = "10.1102/1470-7330.2011.0009",
language = "English (US)",
volume = "11",
pages = "37--41",
journal = "Cancer Imaging",
issn = "1740-5025",
publisher = "e-med",
number = "1",

}

TY - JOUR

T1 - Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma

AU - Saboo, Sachin S.

AU - Krajewski, Katherine M.

AU - Jagannathan, Jyothi P.

AU - O'Regan, Kevin N.

AU - Odze, Robert

AU - Ramaiya, Nikhil

AU - Wolpin, Brian M.

PY - 2011

Y1 - 2011

N2 - Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) is a rare entity comprising 1-14.2% of all primary liver carcinomas. In this report, we present a case of rapid progression of cHCC-CC, a rare tumor in a 77-year-old Caucasian male patient with hepatitis B-induced cirrhosis, moderately elevated alpha fetoprotein, and imaging and pathologic features of a mixed liver tumor. There was no evidence of metastatic disease in the chest, abdomen or pelvis by computed tomography (CT) scan at the time of diagnosis. Needle biopsy of the segment 8 lesion revealed two discrete histologic components to the tumor: well-differentiated HCC and poorly differentiated adenocarcinoma, consistent with intrahepatic CC. The patient rapidly developed metastatic disease after initial local therapy with hepatic arterial chemoembolization and percutaneous cryoablation, dying within 5 months of diagnosis. Radiofrequency ablation, cryoablation and radioembolization with yttrium-90 microspheres remain possible treatment strategies for patients with cHCC-CC unable to undergo surgical resection. The diagnosis and treatment of cHCC-CC can be challenging due to clinical, imaging and histological features that overlap with pure HCC and CC.

AB - Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) is a rare entity comprising 1-14.2% of all primary liver carcinomas. In this report, we present a case of rapid progression of cHCC-CC, a rare tumor in a 77-year-old Caucasian male patient with hepatitis B-induced cirrhosis, moderately elevated alpha fetoprotein, and imaging and pathologic features of a mixed liver tumor. There was no evidence of metastatic disease in the chest, abdomen or pelvis by computed tomography (CT) scan at the time of diagnosis. Needle biopsy of the segment 8 lesion revealed two discrete histologic components to the tumor: well-differentiated HCC and poorly differentiated adenocarcinoma, consistent with intrahepatic CC. The patient rapidly developed metastatic disease after initial local therapy with hepatic arterial chemoembolization and percutaneous cryoablation, dying within 5 months of diagnosis. Radiofrequency ablation, cryoablation and radioembolization with yttrium-90 microspheres remain possible treatment strategies for patients with cHCC-CC unable to undergo surgical resection. The diagnosis and treatment of cHCC-CC can be challenging due to clinical, imaging and histological features that overlap with pure HCC and CC.

KW - Combined hepatocellular carcinoma and cholangiocarcinoma

KW - MRI

UR - http://www.scopus.com/inward/record.url?scp=79959574756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959574756&partnerID=8YFLogxK

U2 - 10.1102/1470-7330.2011.0009

DO - 10.1102/1470-7330.2011.0009

M3 - Article

VL - 11

SP - 37

EP - 41

JO - Cancer Imaging

JF - Cancer Imaging

SN - 1740-5025

IS - 1

ER -